arGEN-X BV (NASDAQ:ARGX) has received a consensus broker rating score of 1.00 (Strong Buy) from the five analysts that cover the stock, Zacks Investment Research reports. Five research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus target price of $91.67 for the company and are expecting that the company will post ($0.31) EPS for the current quarter, according to Zacks. Zacks has also given arGEN-X BV an industry rank of 192 out of 265 based on the ratings given to related companies.

How to Become a New Pot Stock Millionaire

A number of analysts have issued reports on the company. Zacks Investment Research downgraded arGEN-X BV from a “hold” rating to a “sell” rating in a report on Wednesday, March 7th. JMP Securities lifted their price target on arGEN-X BV from $74.00 to $87.00 and gave the stock an “outperform” rating in a report on Monday, January 29th. Finally, Piper Jaffray Companies lifted their price target on arGEN-X BV to $100.00 and gave the stock an “overweight” rating in a report on Tuesday, December 19th.

A hedge fund recently raised its stake in arGEN-X BV stock. Alyeska Investment Group L.P. lifted its position in shares of arGEN-X BV (NASDAQ:ARGX) by 1.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 121,313 shares of the company’s stock after purchasing an additional 2,167 shares during the period. Alyeska Investment Group L.P. owned about 0.45% of arGEN-X BV worth $2,743,000 at the end of the most recent reporting period. Institutional investors own 44.94% of the company’s stock.

Shares of arGEN-X BV (ARGX) opened at $79.71 on Tuesday. arGEN-X BV has a fifty-two week low of $17.33 and a fifty-two week high of $87.00.

COPYRIGHT VIOLATION WARNING: “Analysts Anticipate arGEN-X BV (ARGX) to Post ($0.31) EPS” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/analysts-anticipate-argen-x-bv-argx-to-post-0-31-eps/1961471.html.

About arGEN-X BV

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Get a free copy of the Zacks research report on arGEN-X BV (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for arGEN-X BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for arGEN-X BV and related companies with MarketBeat.com's FREE daily email newsletter.